Here, we review current hydroxychloroquine screening guidelines and controversies regarding specific screening tests and acceptance of the guidelines. Screening tests are described, and their predictive results are analysed, with special emphasis on early changes. Further research is needed to come to a conclusion about the efficacy of the new proposed dose.
MorsmanCDGLiveseySJRichardsIMJessopJDMillsPV.Screening for hydroxychloroquine retinal toxicity: is it necessary?Eye (Lond)1990;
4: 572–576.
2.
LevyGDMunzSJPaschalJCohenHBPinceKJPetersonT.Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum1997;
40: 1482–1486.
3.
MarmorMFKellnerULaiTYMellesRBMielerWF; American Academy of Ophthalmology.Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology2016;
123: 1386–1394.
PhamBHMarmorMF.Sequential changes in hydroxychloroquine retinopathy up to 20 years after stopping the drug: implications for mild versus severe toxicity. Retina2019;
39: 492–501.
7.
AllahdinaAMChenKGAlvarezJAWongWTChewEYCukrasCA.Longitudinal changes in eyes with hydroxychloroquine retinal toxicity. Retina2019;
39: 473–484.
8.
WolfeFMarmorMF.Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken)2010;
62: 775–784.
9.
MellesRBMarmorMF.The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol2014;
132: 1453–1460.
10.
GrassmannFBergholzRMändlJJägleHRuetherKWeberBH.Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy). BMC Ophthalmol2015;
15: 18.
11.
ShroyerNFLewisRALupskiJR.Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?Am J Ophthalmol2001;
131: 761–766.
12.
MavrikakisISfikakisPPMavrikakisE, et al.
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology2003;
110: 1321–1326.
13.
BrowningDJLeeC.Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. Clin Ophthalmol2014;
8: 1389–1399.
14.
GordonCAmissah-ArthurM-BGayedM, et al.
The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford)2018;
57: e1–e45.
15.
Ruiz-IrastorzaGKhamashtaM.Hydroxychloroquine: the cornerstone of lupus therapy. Lupus2008;
17: 271–273.
16.
Ruiz-IrastorzaGRamos-CasalsMBrito-ZeronPKhamashtaMA.Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis2010;
69: 20–28.
17.
MokCCTseSMChanKL, et al.
Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus2018;
27: 7227.
18.
AlarconGSMcGwinGBertoliAM, et al.
Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis2007;
66: 1168–1172.
19.
SinghDKMuhieddineLEinstadterDBallouS.Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine. Rheumatol Adv Pract2019;
3: rkz009.
20.
FanouriakisAKostopoulouMAlunnoA, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019;
78: 736–745.
21.
GreensteinVCAmaro-QuirezaLAbrahamESRamachandranRTsangSHHoodDC.A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy. Doc Ophthalmol2015;
130: 13–23.
22.
PinckersACruysbergJRAan de KlerkAL.Main types of bull’s eye maculopathy. Functional classification. Doc Ophthalmol1984;
58: 257–267.
